Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vivatlac Baby on Crying Behavior of Colicky Babies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed for infantile colic according to Wessel's criteria~Exclusion Criteria:~* previous treatment with probiotic or synbiotic~* previous treatment with antibiotics

- Gender: ALL
- Minimum Age: 3 Weeks
- Maximum Age: 6 Weeks
- Healthy Volunteers: f

Study Arms:
- Simethicone Solution (Type: ACTIVE_COMPARATOR): Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
- Vivatlac Baby (Type: EXPERIMENTAL): Treatment with one stick pack of the multi-strain synbiotic (Vivatlac® Baby, Vivatrex GmbH, Rees, Germany) per day for four weeks. Each stick pack of Vivatlac® Baby contains a total of 10\^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.

Based on this trial design, predict the completion outcome and termination type (if applicable).